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Considerable insight into the structural and genetic bases of antibody specificity 
has come from studies of the homogeneous immunoglobulin products of mono- 
clonal B cell disorders, especially those proteins of defined antibody specificity. 
The seminal finding of Kunkel and co-workers (1,  2) that human monoclonal 
autoantibodies express distinctive isotypic and cross-idiotypic determinants and 
have common structural features provided the initial evidence for a  genetically 
restricted immune response in man to self antigens. Their studies demonstrated 
that the light (L)  1 chains of monoclonal IgMK cold agglutinins and of IgMx anti- 
IgG autoantibodies, i.e., rheumatoid factors (RFs), were predominantly members 
of the V  region subgroup  V,ni (2-4);  the similarity among these proteins was 
also evidenced by the finding that  10 of the  16 KIII chains from the IgMx RFs 
had properties associated with the serologically and chemically defined xIIIb sub- 
subgroup (5,  6).  Sequence analyses of IgM RFs also demonstrated extensive V 
region  similarities among proteins  expressing  cross-reactive  idiotypic determi- 
nants (7, 8). 
Our immunochemical and biochemical analyses of 10 monoclonal IgMx pro- 
teins  isolated  from  IgM-IgG cryoprecipitable  immune complexes (9,  10)  con- 
firmed the  observation  of Kunkel et  al.  (2)  by demonstrating that their light 
chains were KIIIb (10). Further evidence for the preferential association of xIIIb 
light chains with monoclonal IgMx autoantibodies was obtained by our finding 
that the light chains of three IgMK anti-low density lipoprotein (LDL) antibodies 
were also members of the KIIIb sub-subgroup.  Partial amino acid sequence data 
on all 13 K cbains revealed marked similarities in primary structure (10). 
To establish the extent of homology among the K  chains of IgMK autoantibod- 
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ies,  we  have  determined  the  complete  light  chain variable  region  amino acid 
sequence  from four such  light chains:  two were  from  IgMK RFs and one was 
from an  IgMK anti-LDL antibody;  the  fourth  K chain  sequenced  was  isolated 
from an IgMK protein that bound specifically intermediate filaments. Our finding 
that the amino acid sequence of that portion of the VL region encoded by the V 
gene  segment  (positions  1-95)  of all  four  ~  light  chains  is  virtually identical 
provides further evidence that the V~mb germ line gene is selected preferentially 
in the human IgM autoimmune response. 
Materials and Methods 
Isolation ofMonoclonal IgMK Proteins.  Plasma was obtained by plasmapheresis of four 
patients: Two (GAR and GOT) had mixed cryogiobulinemia, patient SON had lympho- 
cytic lymphoma and cryoglobulinemia, and patient PIE had Waldenstr6m's macroglobu- 
linemia. For proteins SON, GAR, and GOT,  maximum cryoglobulin precipitation was 
obtained by maintaining the serum at 4°C for 48 h, after which the cryogiobulins were 
isolated by centrifugation at 4 ° C. The cryoprecipitates were washed with cold phosphate- 
buffered saline (PBS), pH 7.0, as previously described (11). Protein PIE was obtained as 
a euglobulin (12). The cryoprecipitates SON, GAR, and GOT were dissolved in 0.1  M 
acetic acid (HAc) and gel filtered at room temperature through a G-200 Sephadex column 
(140  × 4 cm) equilibrated in 0.1  M HAc. Protein PIE was dissolved in PBS, gel filtered 
at room temperature through a  G-200  Sephadex column (150  x  4  cm) in  PBS,  and 
reprecipitated as a euglobulin. The IgM-containing fractions, identified by immunodif- 
fusion analyses, were pooled, and their purity was determined via electrophoresis on 0.1% 
sodium dodecyl sulfate (SDS)-I 0% polyacrylamide gels and by immunodiffusion analyses 
with monospecific anti-heavy chain and anti-light chain antisera. The IgM proteins were 
assayed for anti-IgG activity via  the  latex fixation test and  for anti-LDL activity via 
immunodiffusion analysis with purified LDL, very low density lipoprotein (VLDL), high 
density lipoprotein (HDL), and with apolipoprotein B. The binding of IgMK protein PIE 
to intermediate filaments was demonstrated immunohistologically  by Dr. Max D. Cooper 
who generously supplied plasma from this patient for our studies. 
Isolation and Characterization of  Light Chains  from Monoclonal IgM Proteins.  Light chains 
were  obtained  from  partially  or  completely reduced  IgM  proteins  by dissolving  the 
lyophilized preparations in an "incomplete" reduction buffer (27 mM Tris-HCl, pH 8.2, 
containing I0 mM dithiothreitol) or in a "complete" reduction buffer (6 M guanidine-27 
mM Tris-HCl, pH 8.2, containing 20 mM dithiothreitol), respectively. The solutions were 
maintained for 1 h at 37 °C, and the proteins alkylated by the addition of iodo (14C) acetic 
acid (0.7  mCi/mmol; New England Nuclear, Boston, MA) to final concentrations of 22 
mM and 44 mM, respectively. After 1 h at 37°C, the protein solutions were dialyzed for 
three days against distilled water and lyophilized. The light chains were isolated by gel 
filtration of completely reduced and alkylated IgM proteins through a G-100 Sephadex 
column (165  x  3 cm) in  1 M HAc-5M guanidine and repurified by high performance 
liquid chromatography (HPLC). Their purity was established via SDS-polyacrylamide gel 
electrophoresis. The x light chains obtained from partially reduced IgM proteins were 
analyzed via immunodiffusion analyses with antisera rendered specific  for each of the 
four VK region subgroups, V~,, V,,, V~m, and V,~v (3), and with antisera that recognized 
antigenic determinants associated with proteins of the ~IIIb sub-subgroup (5, 6). 
Enzymatic Digestion and Purification of  Peptides.  Completely reduced and (14C) alkylated 
light chains were dissolved (10 mg/ml) in 0.2 M ammonium bicarbonate, pH 8.0, and the 
proteins digested with bovine TPCK-treated trypsin (Sigma Chemical) at  1:100  (wt/wt) 
enzyme/protein ratio. The digestion was performed at 37°C and after 20 min proteolysis 
was  terminated by adding distilled water  and  freeze  drying the  sample.  The  tryptic 
peptides were separated at room temperature by HPLC (Waters Assoc.,  Milford, MA), 
using a  reverse phase  support  medium, /~Bondapak  C~s, 7.8  mm X  30  cm  (13).  The 
peptides were eluted at a flow rate of 2 ml/min using a 60-min-linear gradient generated PONS-ESTEL ET  AL.  895 
by mixing  0.05% trifluoroacetic acid (TFA) with 0.05% TFA/acetonitrile  1:2 (vol/vol). 
The  column effluent was monitored by absorbance at  210  nm,  and  the radioactivity 
determined by scintillation  counting (Beckman  LS-250).  When necessary,  the peptides 
were repurified on a #Bondapak C,s column 3.9 mm ×  30 cm; the optimum times and 
TFA-TFA/acetonitrile  linear  gradients  used were determined  by the  elution  profiles 
obtained during the initial separation procedures. 
Amino Acid Analysis.  The tryptic peptides were hydrolyzed under reduced pressure in 
0.2 ml of 6 M HCI for 20 h at  110°C (40 #1 of a  1% aqueous solution  of phenol were 
added to prevent tyrosine degradation) and their amino acid composition  determined on 
a Durrum D-500 automatic amino acid analyzer (Dionex, Sunnyvale, CA) (13). 
Amino Acid  Sequence Analysis.  Automated amino  acid  sequence analyses  were per- 
formed on  a  Beckman  890C  sequencer using  a  0.1  M  Quadrol  program.  For  small 
peptides,  polybrene was added to the cup (14). Phenylthiohydantoin (PTH) amino acids 
were identified by HPLC with the use of a Waters ~Bondapak C18 column, 3.9 mm × 30 
cm, using a linear gradient generated by mixing solvent A, composed of 14% methanol-- 
0.2% acetic acid (brought to pH 4.5 with triethylamine),  and solvent B, of 90% methanol-- 
0.025% acetic acid,  and by automated amino acid analysis, after back-hydrolysis of the 
derivatives  in  0.2 ml  of 6  M HCI--5 #! 5%  SnCI2 under reduced pressure for 4 h at 
150°C. Cysteine  was also detected by counting the radioactivity  of PTH (14C) carboxy- 
methylcysteine  in a liquid scintillation counter. 
Results 
The  completely reduced  and  (14C) alkylated  light  chains  were  subjected to 
automated amino acid sequence analyses from which were determined the first 
62 residues of proteins SON, GAR, and GOT, and the first 63 of protein  PIE 
(Fig.  1). The amino terminal  sequence of all four proteins was identical except 
for an arginyl residue at position 29 in K chain GOT and an asparaginyi residue 
at position 60 for K chain SON. 
Completely reduced and (~4C) alkylated light chains from each protein  were 
digested with  trypsin and  the resultant  peptides purified  by HPLC.  20  tryptic 
peptides, T1-T20, were obtained from each protein; their amino acid composi- 
tions are shown in Tables I and II. The ~ chain V region residues (positions  1- 
108) were contained in peptides T1-T9; their order was readily ascertained by 
automated sequence analysis of each peptide separated by HPLC (Fig. 2). Tryptic 
peptides, T l-T5,  included the first 61  residues and,  in all  four proteins,  were 
identical  in composition and  in sequence except for the two differences noted 
above.  As  expected,  the  presence  of the  trypsin-sensitive  arginyl  residue  at 
position 29 in protein GOT yielded, for T3, two peptides T3a and T3b, which 
contained  residues from positions  25-29  and  30-45,  respectively. Peptide T6 
contained the residues located from positions 62-77; these were identical in all 
four proteins.  The elution profiles of peptide T7 from proteins SON, PIE, and 
GAR (and peptide T7a from protein GOT) differed, ranging from 58% to 62% 
of the  TFA-TFA/acetonitrile  linear  gradient  (Fig.  9).  For  K chain  GOT,  the 
presence of a trypsin-sensitive arginyl residue at position 96 resulted in two T7 
peptides,  T7a  and  T7b.  The  sequences  of these  peptides,  which  contained 
residues located from positions  78-103,  including  the radiolabeled cysteine at 
position  88,  was similar  for all  three  proteins and  for protein  GOT except at 
position  96,  where  each  of the  four proteins  had  a  different  residue,  and  at 
position  100,  where K chain SON differed from proteins PIE, GAR, and  GOT 
by having a  glycyl instead of a  glutamyl residue.  Protein SON was also unique S
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FIGURE  2.  Purification  of the  tryptic  peptides  of x  chain  SON  (  ),  PIE  (---),  GAR 
( ......  ), and GOT ( .....  ) by H PLC (see text). The asterisk indicates '4C-labeled peptides. 
by virtue of an additional prolyl residue located in sequence between positions 
95 and 96. The elution profile of peptide T8 (positions 104-107) from proteins 
PIE and SON could be distinguished from proteins GAR and GOT (Fig. 2). The 
amino terminal residue of peptide T8' was valyl for proteins PIE and SON and 
of peptide TS" was leucyl for proteins GAR and GOT. Peptide T9 contained a 
free arginyl residue (Table I) and was assigned on the basis of sequence homology 
with other r light chains (3) to position 108, which is located at the end of the V 
region. The complete V region sequence of K  chains, SON, PIE, GAR, and GOT 
is presented in Fig.  1. 
The light chain constant region  (C) residues  (positions  109-214)  were con- 
tained in peptides T10  to T20  (Table  II).  The complete sequence of peptide 
T10  (positions  109-126)  was determined for protein SON and up to position 
116 for the other three proteins; these data are included in Fig. 1. The sequences 
were identical to that of the C  region of human K chains (3).  The amino acid 
compositions of peptides T10-T20  were identical except for T18'  and T18". 
Because this peptide and peptide T14 contain the residues associated with the 
Km allotypic markers, Kin(l), Km(1,2), and Km(3) (15), these two peptides were 
partially sequenced. Proteins GAR, GOT, and PIE had alanyl and valyl residues 
at  positions  153  and  191,  respectively,  which  is  characteristic  of the  Km(3) 
allotype, and protein SON, at these same two positions had the alanyl and leucyl 
residues found for K chains of the Km(1,2) aliotype. 
Discussion 
Our  determination  of the complete V  region amino acid  sequence of light 
chains obtained from four human IgMK autoantibodies has provided confirma- 
tional data on the remarkably similar primary structure evidenced through partial 900  RESTRICTION  OF  THE  HUMAN  AUTOIMMUNE  RESPONSE 
sequence analysis of 13 such light chains (10).  Proteins GAR, GOT, and SON 
(shown previously to be virtually identical in sequence to position 61), differed 
at only few residues of the 108 positions that constitute the entire VL region. An 
even closer similarity in sequence among these three K chains was evident from 
positions  1-95,  which include the portion of the V  region encoded by the V 
gene segment (16,  17). The two RF light chains, GAR and GOT, were identical 
in sequence except at position 29 and otherwise differed by only one residue 
from the anti-LDL light chain SON at position 60 located in the third framework 
region (FR3). Protein SON also contained an additional residue located between 
positions  95  and  96,  the  site  of combinatorial joining between  the  V  and J 
(joining) gene segments (16,  17).  It is noteworthy that the V segment-encoded 
sequence of the fourth K chain, PIE, was completely identical to that of protein 
GAR even though the two IgM proteins had different antigen binding specifici- 
ties. The V segment sequence of two other K light chains from IgMK RFs, WOL 
and SIE, determined by Andrews and Capra (8), is also very similar to that of 
proteins GAR and GOT. The extensive V segment sequence homologies of these 
Kill  chains and  of Kill  Bence Jones proteins  (3)  suggest that proteins of this 
subgroup are  encoded by a  relatively  small  number of Vail  germ  line genes. 
Indeed, cloning experiments with V, gene probes indicate that the number of 
V~ germ line genes in the human genome is relatively small, estimated to be <50 
(17-19).  The nucleotide sequence of the V,m cDNA probe NG9 (18) specifes a 
V  segment amino acid sequence identical to that of protein GAR except for a 
threonyl/seryi  interchange  at  position  52  in  the  CDR2, an  alanyl/seryi  inter- 
change at position 66 in the FR3, and an asparaginyl/seryl and a glutamyl/prolyl 
interchange at positions 93 and 95, respectively, in the CDR3. 
The KIIIb sub-subgroup expresses an antigenic determinant that permits them 
to be readily distinguished serologically from other chemically defined Kill chains 
designated KIIIa, or from Kill chains with more extensive V  segment sequence 
differences,  e.g.,  the  Kill  chain  from  the  IgM  RF  protein  POM  (7), 2 which 
differed from protein GAR by 20 residues. Light chains classified immunochem- 
ically as Kill and KIIIb have been identified among Ig molecules from normal 
individuals, indicating the isotypic nature  of the V, region subgroup and sub- 
subgroup (5,  6).  The Kill  subgroup constitutes almost one-third (30%) of the 
normal K chain population of which approximately one-half (45-55%) are KIIIb 
proteins. Among IgMK proteins that lacked demonstrable anti-IgG or other types 
of autoantibody activity,  the  frequence  of occurrence  of Kill  and  KIIIb  light 
chains was found to be similar. In contrast, among 33 anti-IgG,  3 anti-LDL,  1 
anti-intermediate filament, and  1 anti-smooth muscle (unpublished data)  IgMK 
autoantibodies,  36 (95%) had Kill light chains and of this subgroup, 26 (72%) 
were KIIIb (2,  10).  Whether Kill  (KIIIb) light chains have a  special functional 
significance to account for their predominance among IgMK autoantibodies is 
presently unknown. The CDR1  of Kill  (and KI) proteins is characterized  by a 
lesser number of residues than is found for the CDR1  of KII and KIV proteins 
(3), implying a structural relationship between the configuration of the antigen 
binding site and the light chain isotype. 
2 The IgMK RF POM contained the cross-reactive idiotype Po, in contrast to the IgM~ RFs WOL 
and SIE proteins that shared the cross-reactive idiotype Wa (2). PONS-ESTEL  ET  AL.  901 
The major site of sequence difference among the four K light chains SON, 
PIE,  and  GAR,  and  GOT  is  at  position 96,  where  each  protein possesses a 
distinctive amino acid residue (Fig. 1). This residue is a transcription product of 
the nucleotide triplet contributed by V  and J  genes (16);  however, as shown 
schematically in Fig. 3, alternations in recombination of the 3' and 5' ends of 
the V and J gene segments, respectively, generates additional VL region diversity 
and  can  account  for  the  observed  sequence differences, ihcluding the  extra 
residue at position 95A of protein SON. The tertiary structural features of the 
antigen binding site can be profoundly influenced by the chemical nature of the 
residue at position 96 of the light chain as evidenced from x-ray crystallographic 
analyses of F(ab')u fragments and VL dimers (20,  21). This residue, located in 
the hapten-binding site of CDR3, also interacts with the comparable residue in 
the VH,  thereby also affecting heavy-light chain  interactions,  including their 
preferential homologous reassociation. 
The sequence from positions 97-108 of the J  gene segment-encoded region 
of proteins GAR and GOT was identical and specified by the J,2 germ line gene; 
the comparable segments in proteins SON and PIE were products of the J,4 and 
J~l genes, respectively (22). In addition to the residue at position 96, the J gene- 
'E 
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i, 
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FIGURE 3.  Schematic  representation of V-J combinatorial joining through pairing of the 
palindromic sequences of the 3' non-coding DNA region of the germ line VK gene with the 
5' non-coding  DNA region of the Jx genes 1, 2, and 4 (16, 17, 22). The amino acid sequences 
transcribed by V and J genes are indicated by solid and interrupted lines, respectively. 902  RESTRICTION OF  THE  HUMAN AUTOIMMUNE RESPONSE 
encoded segment also contains, in FR4, at least two contacting residues involved 
in VL-VH association (20). 
The role of the heavy chain in determining the antigen binding specificity of 
IgM autoantibodies remains to be established. The determination of the complete 
amino acid VH sequence of these four and of other monocional autoantibodies 
as  well  as  the  production  of antiidiotypic antibodies  (in  progress  in  our  lab) 
should provide further  insight into the structural  features responsible for  the 
preferential  association  of  light  and  heavy  chain  isotypes,  the  expression  of 
idiotypic determinants, and the chemical nature of the antigen binding site. The 
preferential  association  of  particular  light  and  heavy  chains  among  human 
monoclonal IgM autoantibodies implies a genetic control of the immune response 
to self antigens. Jerne  (23) has proposed that specific isotypic and/or idiotypic 
features of homogeneous Igs participate in a network of cellular interactions by 
which the immune response is regulated. Support for this hypothesis has come 
from the demonstration of cross-reactive idiotypes in the autoimmune response 
elicited in inbred mice (24-27) and among human autoantibodies (e.g., the Wa 
and Po cross-reactive idiotypes present among monoclonai IgM RFs) (2). Contin- 
ued studies of monoclonai IgM autoantibodies should provide further  insight 
into the structural,  genetic, and evolutionary factors that control the immune 
response to self antigens. 
Summary 
Light chains of the seroiogically and chemically defined V region sub-subgroup 
KI IIb are preferentially associated with several types of human IgMK (monocional) 
autoantibodies  and  are  remarkably  homologous in  primary  structure,  as  evi- 
denced by partial amino acid sequence data. To establish the extent of homology 
among such  proteins,  we  have  determined  the  complete  variable  region  (V) 
sequence of the light chains of four monoclonal IgMK autoantibodies, of which 
two (GAR and GOT) are rheumatoid factors (RFs), the third (SON) has anti-apo 
/3 iipoprotein specificity, and the fourth (PIE) binds specifically to intermediate 
filaments. The region encoded by the V~ segment gene (positions  1-95)  in all 
four  light  (L)  chains  is  virtually  identical  in  sequence,  differing by  only one 
residue  in  the  FR3  of protein  SON  and  in  the  first  CDR  of protein  GOT. 
Further, the CDR3 of K  chain SON contains an additional residue (prolyl) located 
at the carboxyl-terminus of the V  segment. The region encoded by the J  gene 
(positions 96-108) is identical after position 96 for the two RFs GAR and GOT 
(J~2), but different in proteins SON (J~4) and PIE (JA). The amino acid residue 
at position 96, located in CDR3 at the site of combinatorial joining of the V, and 
J~ gene segments and involved as a contacting residue in the hapten binding site, 
is  different  in  all  four  light  chains.  These  results  demonstrate  the  extensive 
homology in sequence among light chains of IgMK autoantibodies and indicate 
that a particular V, germ line gene, KIIIb, is expressed as a phylogenetic response 
to certain self antigens or as part of a  selection process by which these autoim- 
mune responses are regulated. 
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